Filter and export

Publications

468 Publications visible to you, out of a total of 468
Health Information Systems
Management of health information systems

Abstract

Not specified

Author: Alfred Winter

Date Published: 2004

Publication Type: InCollection

Ein 3LGM^2-Modell des Informationssystems des Universitätsklinikums Leipzig und seine Anwendung im Informationsmanagement
Management of health information systems

Abstract

Not specified

Authors: T. Wendt, B. Brigl, A. Häber, Alfred Winter

Date Published: 2004

Publication Type: InCollection

Modeling Hospital Information Systems (Part 2): Using the 3LGM2 Tool for Modeling Patient Record Management
Management of health information systems

Abstract

Not specified

Authors: T. Wendt, A. Häber, B. Brigl, Alfred Winter

Date Published: 2004

Publication Type: Journal article

Rahmenkonzept für die Weiterentwicklung des Informationssystems der Medizinischen Fakultät der Universität Leipzig 2004-2005
Management of health information systems

Abstract

Not specified

Author: Alfred Winter

Date Published: 2004

Publication Type: Misc

Ein 3LGM^2 Modell des Krankenhausinformationssystems des Universitätsklinikums Leipzig und seine Verwertbarkeit für das Informationsmanagement
Management of health information systems

Abstract

Not specified

Authors: B. Brigl, A. Häber, T. Wendt, Alfred Winter

Date Published: 2004

Publication Type: InCollection

Modellierung von Informations- und Kommunikationsprozessen zur Unterstützung des Informationsmanagements im Krankenhaus
Management of health information systems

Abstract

Not specified

Authors: B. Brigl, A. Strübing, Alfred Winter

Date Published: 2004

Publication Type: InCollection

Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
GLA - German Lymphoma Alliance

Abstract (Expand)

BACKGROUND: There is evidence that intensified variants of the classical 3-weekly CHOP-21 chemotherapy [cyclophosphamide (C), doxorubicin (H), vincristine (O), prednisone (P)] may improve treatment … outcome in aggressive lymphoma. Three variants using either an addition of etoposide (CHOEP-21: 100 mg/m(2) on days 1-3), the shortening to 2-week intervals using recombinant human granulocyte colony-stimulating factor (rhG-CSF; CHOP-14) or both (CHOEP-14) are currently compared with CHOP-21 in the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). To enable more extensive testing of these schemes we here characterise their practicability regarding schedule adherence, acute haematotoxicity and need for supportive treatment. PATIENTS AND METHODS: The trial included patients with normal lactate dehydrogenase (LDH) aged </=60 years (NHL-B1) and patients aged 61-75 years (NHL-B2). The data are taken from an interim analysis. Data from 959 patients (CHOP-21: 232; CHOP-14: 238; CHOEP-21: 244; CHOEP-14: 245) from 162 institutions with a total of 5331 therapy cycles were evaluated. RESULTS: The dose adherence in the NHL-B1 trial was excellent. The median relative dose (RD; i.e. actually given compared to planned dose) exceeds 98% for the myelosuppressive drugs in all four regimens. Only </=5% of patients received a relative dose <80% (RD <80). The median treatment duration could be shortened as scheduled for both CHOP-14 by 36 days and CHOEP-14 by 35 days. The dose adherence in the NHL-B2 trial was excellent for CHOP-21 and CHOP-14 for the myelosuppressive drugs (median RD >/=98%, RD <80 </=15%). Addition of etoposide, however, was accompanied by more dose erosion (median RD >/=97%, RD <80 </=17% for CHOEP-21 and </=27% for CHOEP-14). The median treatment duration could be shortened by 34 days with CHOP-14 compared with CHOP-21. Less treatment shortening was feasible for CHOEP-14 compared with CHOP-21 (median of 29 days). CHOP-14 and CHOP-21 were similar regarding toxicity profile, rate of infection, use of antibiotics, rate of transfusions and hospitalisation. CHOEP schemes were associated with a higher rate of infections, more transfusion requirements, more antibiotic use and longer hospitalisation than the CHOP schemes, particularly in patients aged >60 years. Haematopoietic recovery was age- and treatment-related. CONCLUSIONS: CHOP-14 with the addition of rhG-CSF is safe and practicable in a large multicentre setting in patients aged 18-75 years. Despite shorter treatment intervals it can be delivered at the same dose as the classical 3-weekly CHOP with a comparable toxicity profile. The addition of etoposide is feasible and safe for patients </=60 years old in both the CHOEP-21 and CHOEP-14 schemes. For patients >60 years of age the addition of etoposide is associated with marked dose erosion due to increased toxicity. In this age group CHOEP should be used with caution.

Authors: A. Wunderlich, M. Kloess, M. Reiser, C. Rudolph, L. Truemper, S. Bittner, H. Schmalenberg, R. Schmits, M. Pfreundschuh, M. Loeffler

Date Published: 11th Jun 2003

Publication Type: Not specified

Human Diseases: non-Hodgkin lymphoma

Navigate

Health Atlas - Local Data Hub/Leipzig

The Health Atlas - Local Data Hub/Leipzig is an alliance of medical ontologists, medical systems biologists and clinical trials groups to design and implement a multi-functional and quality-assured atlas. It provides models, data and metadata on specific use cases from medical research fields.

Registered Repository

re3data.org Badge
Powered by
 (v.1.13.0-master)
Health Atlas | Funding and Programmes | Credits | Terms & Conditions | Privacy Policy | Imprint
Copyright © 2008 - 2021 The University of Manchester and HITS gGmbH
Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig

By continuing to use this site you agree to the use of cookies